We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Delivers a Preliminary No to Opdivo/Yervoy Combination for Lung Cancer
NICE Delivers a Preliminary No to Opdivo/Yervoy Combination for Lung Cancer
The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a preliminary rejection of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) as a combination treatment for lung cancer in as-yet untreated patients.